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DNA hypomethylation may increase the risk of colorectal cancer. The main aim of this study was to assess the influence of folate
status (serum and erythrocyte folate and plasma homocysteine concentrations) on DNA methylation. Methylenetetrahydrofolate
reductase (MTHFR 677C-T and 1298A-C), methionine synthase (MS 2756A-G) and cystathionine synthase (CBS 844ins68)
polymorphisms were measured to account for potential confounding effects on folate status and DNA methylation. A total of 68
subjects (33 men and 35 women, 36–78 years) free from colorectal polyps or cancer were recruited in a cross-sectional study.
Tissue biopsies were obtained at colonoscopy for the determination of DNA methylation in colonic mucosa using an in vitro
radiolabelled methyl acceptance assay. Serum and erythrocyte folate were inversely correlated with plasma homocysteine
(r¼ 0.573, Po0.001 and r¼ 0.307, P¼0.01 respectively) and DNA hypomethylation in colonic mucosa (r¼ 0.311, P¼0.01
and r¼ 0.356, P¼0.03). After adjusting for gender, age, body mass index, smoking and genotype, there were weak negative
associations between serum and erythrocyte folate and colonic DNA hypomethylation (P¼0.07 and P¼0.08, respectively).
British Journal of Cancer (2005) 92, 838–842. doi:10.1038/sj.bjc.6602439 www.bjcancer.com
Published online 22 February 2005
& 2005 Cancer Research UK
Keywords: folate; homocysteine; DNA methylation; colorectal cancer; genotype; MTHFR; MS; CBS
                                             
A low dietary intake of folate has been associated with increased
risk of colorectal adenoma and cancer in prospective cohort
(Giovannucci et al, 1993; Giovannucci et al, 1995; Giovannucci
et al, 1998; Terry et al, 2002) and case–control (Benito et al, 1991;
Benito et al, 1993; Tseng et al, 1996; Keku et al, 2002; Boyapati et al,
2004) studies. Furthermore, low serum (Bird et al, 1995; Kato et al,
1999) and erythrocyte folate concentrations (Lashner, 1993; Bird
et al, 1995; Paspatis et al, 1995) have been reported to be associated
with the development of adenoma or cancer.
Hypomethylation of DNA induced by a lack of folate may
predispose to genetic defects associated with the development of
neoplasia (Molloy et al, 2002). The methylation cycle maintains the
level of the methyl donor S-adenosylmethionine (SAM) in cells.
The methyl group is provided to DNA through SAM by
methyltransferases, which vary according to cell type, and the
product of the reaction is S-adenosylhomocysteine (SAH). This is
immediately hydrolysed to homocysteine and adenosine. The
homocysteine can then be either catabolised through cystathionine
synthase (CBS) to pyruvate and used for energy or it can be used
by the enzyme methionine synthase (MS) for recycling back to
methionine and SAM. Methionine synthase has a requirement for a
folate cofactor, 5-methyltetrahydrofolate. An inadequate supply of
folate results in elevations in the plasma and cellular concentra-
tions of homocysteine. This in turn causes an elevation of SAH,
which is a potent inhibitor of all methyltransferase enzymes. Such
inhibition, it is suggested, would impair the methylation of DNA,
leading to changes in normal patterns of DNA methylation that
regulate gene expression.
Hypomethylation at critical sites is associated with oncogene
activation and tumorigenesis (Sharrard et al, 1992), while
hypermethylation of the normally unmethylated CpG islands in
the promoter regions of some tumour suppressor genes prevents
transcription and promotes tumorigenesis (Issa et al, 1994;
Hiltunen et al, 1997; Iacopetta et al, 1997).
Decreased genomic DNA methylation has been reported in
colorectal tumour tissue (Feinberg and Vogelstein, 1983; Goelz
et al, 1985) and normal-appearing colonic mucosa from indivi-
duals with cancer (Cravo et al, 1994). A recent study suggested that
DNA hypomethylation in normal-appearing colonic mucosa is
associated with low folate status and increased risk of colorectal
neoplasia (Pufulete et al, 2003). However, no studies have
investigated the relationship between DNA methylation in colonic
mucosa and folate status in subjects without colorectal adenoma or
cancer.
Several common polymorphisms of the remethylating enzymes
methyltetrahydrofolate reductase (MTHFR), methionine synthase
(MS) and cystathionine synthase (CBS) have been identified. The
MTHFR 677C-T mutation is associated with increased turnover
of folate and elevated plasma homocysteine concentration. Two
studies suggested that leucocyte DNA is hypomethylated in
individuals with low folate status and homozygous for the MTHFR
677C-T mutation (Stern et al, 2000; Friso et al, 2002).
Furthermore, in a recent folate depletion–repletion study, young
women carrying the MTHFR 677 TT genotype had a greater
increase in leucocyte DNA methylation following repletion with
folate than those who did not carry the mutation (Shelnutt et al,
2004). The CBS gene has a variant, 844ins68, which has been linked
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swith decreased plasma homocysteine concentration and thus may
protect against hypomethylation (Shannon et al, 2002). Homo-
zygotes for the MTHFR 677C-T and MS 2756A-G polymorph-
isms have been found to have a lower risk of colorectal cancer
(Chen et al, 1996; Ma et al, 1999), but only in individuals with
adequate folate status and/or low alcohol intake. However, under
conditions of low folate status, risk of colorectal neoplasia may be
higher in individuals homozygous for the MTHFR 677C-T
mutation (Tseng et al, 1996; Levine et al, 2000; Ulvik et al, 2001;
Boyapati et al, 2004). A recent study in Japanese individuals with
cancer has shown that the MTHFR 677C-T and 1298A-C
mutations were linked with promoter hypermethylation in the
cancer tissue (Oyama et al, 2004). Furthermore, patients who were
homozygous for the MTHFR 677C-T mutation had significantly
lower concentrations of folate in their tumour tissue (Kawakami
et al, 2003). To date, no studies have investigated the effect of
genotype on genomic DNA methylation status in healthy colonic
mucosa.
The aim of the present study was to assess the influence of folate
status on DNA methylation in colonic mucosa in subjects without
colorectal adenoma or cancer. Common polymorphisms of the
remethylating enzymes were measured to account for potential
confounding effects of genotype on folate status and DNA
methylation.
MATERIALS AND METHODS
Subjects
Subjects were patients referred for colonoscopy at the Department
of Colorectal Surgery, King’s College Hospital, London, UK.
Exclusion criteria included a previous or current diagnosis of
cancer or colorectal polyps, a strong family history of colorectal
cancer or adenomatous polyposis coli, inflammatory bowel disease
and current or past history of gluten-sensitive enteropathy, clinical
and/or laboratory evidence of intestinal malabsorption, pregnancy,
alcoholism, anaemia (haemoglobin concentration o11.5gdl
 1 for
women and o12.0gdl
 1 for men), low serum B12 concentration
(o180ngl
 1) and use of medication known to antagonise the
metabolism of folate. Subjects were eligible for inclusion in the
study if they showed no abnormality on full colonoscopy. Rectal
bleeding was attributable to the presence of haemorrhoids in
subjects referred for colonoscopy with this symptom. Written
consent was obtained from all subjects.
Prior to the colonoscopy, a fasting venous blood sample was
collected using the vacutainer technique. Blood was collected into
EDTA vacutainers for full blood count, plasma homocysteine and
erythrocyte folate assays and into vacutainers containing no
anticoagulant for determination of serum vitamin B12 and folate
concentrations and liver function tests. For plasma homocysteine,
the vacutainers were chilled on ice and plasma was separated
within 2h of collection and frozen at  701C. Weight and height
were recorded and information on smoking habits, physical
activity levels, current medication and supplement use was
gathered before colonoscopy. During colonoscopy, three mucosal
biopsies were removed from the rectum (about 12cm from the
anal verge) and immediately snap frozen in liquid nitrogen. All
patients had prepared for the colonoscopy by taking orally
administered colonic lavage solution (KleanPrep
s, Norgine,
Harefield, UK).
At 1 week after the colonoscopy, subjects completed a previously
validated short food frequency questionnaire (Pufulete et al, 2002)
to assess habitual intake of alcohol and folate. It was decided that
the FFQ should not be administered at the time of colonoscopy, as
subjects had been fasting and taking bowel preparation and were
anxious about the procedure, which may have affected their
response. The protocol for the study was approved by the Research
Ethics Committees at King’s College Hospital and King’s College
London.
Laboratory methods
Fasting venous blood samples were obtained prior to the
colonoscopy for determination of serum and erythrocyte folate
concentrations, plasma homocysteine and MTHFR 677C-T and
1298A-C, MS 2756A-G and CBS 844ins68 polymorphisms.
Rectal biopsies of normal-appearing mucosa for the determination
of genomic DNA methylation were obtained during the colono-
scopy.
The laboratory methods used to analyse serum and erythrocyte
folate concentrations, plasma homocysteine, genomic DNA
methylation and gene polymorphisms have been described in
detail elsewhere (Pufulete et al, 2003). Genomic DNA methylation
was determined in colonic mucosa using an in vitro methyl
acceptance assay (Balaghi and Wagner, 1993). In this assay, a
decrease in methyl group incorporation in DNA indicates an
increase in methylation status. Within run and between run, CVs
were 5.3 and 8.9%, respectively.
Statistics
Analyses were performed using Intercooled Stata (version 6.0. for
Windows, Stata Corporation, USA). Logarithmic transformations
were used for erythrocyte folate, serum vitamin B12 and plasma
homocysteine as the distribution of these variables was positively
skewed. Analysis of variance was used to compare folate intake,
serum and erythrocyte folate, plasma homocysteine and genomic
DNA methylation for each genotype, after adjusting for gender,
age, body mass index and smoking. The relationships between
continuous variables were examined using the Pearson and
Spearman correlation coefficients.
The relationships between markers of folate status (dietary
folate intake, serum and erythrocyte folate) and each of plasma
homocysteine and genomic DNA methylation in colonic mucosa
were analysed by multiple linear regression with adjustment for
gender, age, body mass index, smoking and genotype.
RESULTS
A total of 68 subjects (33 men and 35 women), aged 36–78 years,
were found to be eligible for the study; their details are shown in
Table 1. Blood counts and serum vitamin B12 concentrations were
all within the normal laboratory range.
Table 2 shows mean values of folate intake, serum and
erythrocyte folate, plasma homocysteine concentrations and
[
3H]methyl incorporation in colonic DNA according to the
genotypes, adjusted for gender, age, BMI and smoking. Allele
frequencies for the MTHFR 677C-T, MTHFR 1298A-C, MS
2756A-G and CBS 844ins68 mutations were 44, 35, 40 and 25%,
respectively. There was heterogeneity between the means for each
of serum folate and plasma homocysteine and alleles of the
MTHFR 677C-T polymorphism (P¼0.007 and P¼0.0002,
respectively), and between [
3H]methyl incorporation in colonic
DNA and alleles of the MS 2756A-G polymorphism (P¼0.05).
The mean serum folate concentration was 45% lower and the mean
plasma homocysteine concentration 110% higher in subjects
homozygous for the T allele of the MTHFR 677C-T genotype
than in those homozygous for the C allele.
[
3H]methyl incorporation in colonic DNA was lower in subjects
carrying the G allele for the MS 2756A-G mutation (by 18 and
28% in subjects homozygous (GG) and heterozygous (AG),
respectively) than in those without the mutation (AA). There
was no influence on [
3H]methyl incorporation in colonic DNA
Folate status and colonic DNA methylation
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sof the MTHFR (677C-T and 1298A-C) and CBS 844ins68
genotypes.
Smokers had higher mean [
3H]methyl incorporation in colonic
DNA than nonsmokers (490 (s.d. 193) BqmgDNA
 1 vs 353 (s.d.
190) BqmgDNA
 1, P¼0.01), and lower folate intakes (303 (s.d.
134) mgday
 1 vs 380 (s.d. 113) mgday
 1, P¼0.03) and serum folate
concentrations (6.9 (s.d. 3.2) mgl
 1 vs 8.8 (s.d. 3.4) mgl
 1,
P¼0.03).
Folate intake was positively correlated with both serum folate
(r¼0.515, Po0.001) and erythrocyte folate concentrations
(r¼0.473, Po0.001). Plasma homocysteine concentration was
positively correlated with age (r¼0.323, P¼0.007) and negatively
correlated with folate intake (r¼ 0.284, P¼0.027), serum folate
(r¼ 0.573, Po0.001), erythrocyte folate (r¼ 0.307, P¼0.01)
and serum vitamin B12 concentrations (r¼ 0.402, P¼0.001).
Multiple linear regression analysis with plasma homocysteine
concentration as the dependent variable showed that gender
(P¼0.05), age (P¼0.05), serum folate (P¼0.001), serum vitamin
B12 (P¼0.002) and MTHFR 677C -T polymorphism (with higher
homocysteine concentration in subjects homozygous for the T
Table 1 Subject characteristics by gender
Men (n¼33) Women (n¼35) All (n¼68)
Age (year)
a 57.6712.1 57.2711.9 57.4711.9
Body mass index (kgm
 2)
a 26.974.1 26.574.9 26.774.5
Total folate intake (mgday
 1)
a 3807137
b 3417106
c 3597123
d
Alcohol intake (gday
 1)
e 5.0 (0.0–47.0)
b 1.5 (0.0–38.0)
c 3.0 (0.0–47.0)
d
Hemoglobin (gdl
 1)
e 14.5 (12.2–17.2) 13.8 (11.9–16.9) 13.8 (11.9–17.2)
Serum folate (mgl
 1)
a 8.173.7 8.373.2 8.273.4
Erythrocyte folate (mgl
 1)
e 289 (143–645) 278 (110–1040) 286 (110–1040)
Serum vitamin B12 (ngl
 1)
e 444 (218–1252) 409 (201–724) 425 (201–1252)
Plasma homocysteine (mmoll
 1)
e 11.4 (6.5–61.4) 9.6 (5.5–25.1) 9.9 (5.5–61.4)
[
3H]methyl incorporation in colonic DNA (Bqmg DNA
 1)
a 3757200 4137201
f 3947200
g
Smoking (n (%))
Current smoker 12 (36) 9 (26) 21 (31)
Nonsmoker 21 (64) 26 (74) 47 (69)
aArithmetic mean7s.d.
b(n¼29).
c(n¼32).
d(n¼61).
eMedian (with range in parentheses).
f(n¼34).
g(n¼67).
Table 2 Mean folate intake, serum folate, erythrocyte folate, plasma homocysteine and [
3H]methyl incorporation in colonic DNA for all subjects and
according to MTHFR, MS and CBS genotypes
Folate intake
(lgday
 1)
a
Serum folate
(lgl
 1)
Erythrocyte
folate (lgl
 1)
Plasma
homocysteine
(lmolL
 1)
[
3H]methyl
incorporation in
colonic DNA
(Bqlg DNA
 1)
b
n (%) Mean (95% CI)
c Mean (95% CI)
c Mean (95% CI)
d Mean (95% CI)
d Mean (95% CI)
c
All 68 (100) 359 (329–390) 8.2 (7.5–9.0) 296 (271–323) 10.9 (9.9–12.0) 394 (352–439)
MTHFR 677C-T
CC 38 (56) 378 (337–419) 9.3 (8.3–10.3) 303 (268–343) 9.9 (8.8–11.1) 381 (321–440)
CT 24 (35) 326 (272–380) 7.4 (6.1–8.7) 279 (236–326) 10.8 (9.3–12.5) 407 (330–484)
TT 6 (9) 362 (260–464) 5.1 (2.5–7.8) 318 (230–438) 20.8 (15.4–28.3) 447 (291–603)
P¼0.35 P¼0.007 P¼0.66 P¼0.0002 P¼0.69
MTHFR 1298A-C
AA 44 (65) 355 (315–394) 8.1 (7.1–9.2) 301 (268–337) 10.8 (9.6–12.2) 408 (352–464)
AC 22 (32) 365 (311–418) 8.3 (6.8–9.8) 291 (247–344) 11.5 (9.6–13.8) 389 (309–468)
CC 2 (3) 395 (226–565) 9.9 (5.1–14.7) 244 (143–417) 7.6 (4.3–13.4) 209 (47–465)
P¼0.91 P¼0.78 P¼0.75 P¼0.37 P¼0.33
MS 2756A-G
AA 41 (60) 354 (315–393) 8.4 (7.3–9.4) 283 (252–318) 10.7 (9.4–12.2) 438 (383–492)
AG 19 (28) 359 (302–415) 8.0 (6.5–9.6) 322 (271–382) 11.5 (9.5–13.9) 317 (233–400)
GG 8 (12) 390 (296–485) 8.2 (5.7–10.7) 304 (230–401) 10.6 (7.8–14.3) 359 (230–489)
P¼0.86 P¼0.94 P¼0.47 P¼0.81 P¼0.05
CBS 844ins68
Wild type 51 (75) 355 (321–390) 8.3 (7.3–9.2) 286 (258–317) 10.8 (9.6–12.0) 404 (352–455)
844ins68 17 (25) 372 (310–435) 8.2 (6.5–9.9) 328 (273–395) 11.4 (9.3–14.0) 372 (282–463)
P¼0.60 P¼0.96 P¼0.22 P¼0.61 P¼0.57
MTHFR¼methylenetetrahydrofolate reductase; MS¼methionine synthase; CBS¼cystathionine synthase.
a(n¼61).
b(n¼67).
cArithmetic or
dGeometric means (with 95% CI
in parentheses) adjusted for gender, age, BMI and smoking. The P-values relate to tests of heterogeneity between the means arising from the relevant F-test statistic in the analysis
of variance table.
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sallele, P¼0.002) were each associated with plasma homocysteine,
independent of body mass index, smoking and other genotypes.
[
3H]methyl incorporation in colonic DNA was positively
correlated with age (r¼0.260, P¼0.03) and plasma homocysteine
(r¼0.256, P¼0.04) and negatively correlated with serum folate
(r¼ 0.311, P¼0.01), erythrocyte folate (r¼ 0.356, P¼0.003)
and serum vitamin B12 concentrations (r¼ 0.218, P¼0.08).
There was no association between [
3H]methyl incorporation in
colonic DNA and alcohol intake (r¼0.013, P¼0.92). Multiple
linear regression analysis with [
3H]methyl incorporation in colonic
DNA as the dependent variable showed a weak positive association
with smoking (P¼0.05), and weak negative associations with each
of serum folate (P¼0.07) and erythrocyte folate (P¼0.08),
independent of gender, age, body mass index and all genotypes.
No other associations were noted.
DISCUSSION
The aim of this study was to determine the contribution of folate
status to genomic DNA methylation in colonic mucosa in subjects
with no colorectal abnormalities. DNA methylation was deter-
mined by measuring [
3H]methyl incorporation in DNA. Thus, an
increase in [
3H]methyl incorporation reflects a decrease in
methylation. The [
3H]methyl acceptance assay is indirect and
only semiquantitative; a known limitation of this assay is that
damaged DNA templates (DNA adducts, strand breaks and abasic
sites) can accept methyl groups in the methylase reaction and may
therefore give a false positive indication of hypomethylation.
Despite this drawback, there was a trend for an association
between DNA hypomethylation, smoking and folate status. It is
well known that the dietary habits of smokers differ from those of
nonsmokers, and in the present study the dietary intake of folate
was lower in the smokers. However, the effects of smoking and
folate appeared to be independent predictors of hypomethylation.
A limitation of the present study is that we did not measure colonic
mucosal folate concentrations. DNA methylation was not asso-
ciated with alcohol intake, which is known to have negative effects
on methyl metabolism and is associated with increased risk of
colorectal cancer (Chen et al, 1996). However, median alcohol
intake in this group of individuals was relatively low. A wider
range of intakes would need to be considered before firm
conclusions on the relationship between DNA methylation and
alcohol intake can be drawn.
Common polymorphisms in remethylating enzymes were
measured to adjust for possible confounding influences on DNA
methylation and folate status. The frequencies of the mutated
alleles for MTHFR 677C-T and 1298A-C were 44 and 35%,
respectively, which were similar to those reported in other
Caucasian populations: 35% for MTHFR 677C-T (Frosst et al,
1995; Gudnason et al, 1998) and 30% for MTHFR 1298A-C (van
der Put et al, 1998). Allele frequencies for MS 2756A-G and CBS
844ins68 were somewhat higher (40 and 25%, respectively) in the
present study compared with 20% (Leclerc et al, 1996) and 8%
(Tsai et al, 1999), respectively, reported in other Caucasian
populations. Individuals carrying the G allele for the MS
2756A-G genotype had higher genomic DNA methylation status
in colonic mucosa, although DNA methylation was slightly higher
in heterozygotes (AG) than in those homozygous for the G allele
(GG). This finding lends some support to the observation of an
inverse association between the MS 2756A-G genotype and
colorectal cancer risk (Ma et al, 1999). Several studies have also
shown that plasma homocysteine concentrations are lower in
subjects carrying the G allele (Harmon et al, 1999; Chen et al,
2001). This may indicate some benefit associated with this
polymorphism, although to date the functional consequences for
enzyme activity of the MS 2756A-G genotype are unclear.
In the present study, we were unable to demonstrate any
influence of the MTHFR 677C-T and MTHFR 1298A-C, and
CBS 844ins68 genotypes on DNA methylation but the number of
subjects homozygous for the two MTHFR polymorphisms or
carrying the CBS 844ins68 was small. A much larger and
appropriately designed study would be required to investigate
the effects of common genetic variations on DNA methylation and
to assess any gene–gene interactions. However, the findings of the
multiple regression analysis suggest that folate status may be a
stronger determinant of colonic DNA methylation than genotype.
In colorectal tumours, genomic DNA hypomethylation is often
associated with altered methylation patterns in CpG islands in the
promoter regions of critical genes. Promoter hyper- and hypo-
methylation has been shown to silence tumour suppressor genes
(Hiltunen et al, 1997) and activate oncogenes (Sharrard et al,
1992), respectively. Future studies should investigate the possible
link between folate and CpG island methylation, particularly since
there is evidence suggesting that CpG island hypermethylation in
critical genes (e.g., oestrogen receptor, ER; mismatch repair,
MLH1) occurs in normal colonic mucosa (Issa et al, 1994;
Nakagawa et al, 2001).
In conclusion, this study suggests that folate status may be a
determinant of the methylation status of genomic DNA in colonic
mucosa and provides evidence for a plausible mechanism through
which folate may influence risk of colorectal cancer. However, the
small sample size precludes any definitive conclusions to be
drawn. The findings of this pilot study require confirmation in a
larger prospective cohort study.
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